Additionally, the 36-month beta value for CNTA is 1.38. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CNTA is 59.77M and currently, short sellers hold a 2.91% ratio of that float. The average trading volume of CNTA on April 12, 2024 was 400.39K shares.
CNTA) stock’s latest price update
The stock price of Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) has surged by 6.46 when compared to previous closing price of 11.15, but the company has seen a 14.46% gain in its stock price over the last five trading sessions. InvestorPlace reported 2024-03-18 that Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
CNTA’s Market Performance
CNTA’s stock has risen by 14.46% in the past week, with a monthly rise of 9.30% and a quarterly rise of 70.30%. The volatility ratio for the week is 6.78% while the volatility levels for the last 30 days are 7.38% for Centessa Pharmaceuticals plc ADR The simple moving average for the past 20 days is 6.84% for CNTA’s stock, with a 53.19% simple moving average for the past 200 days.
Analysts’ Opinion of CNTA
Many brokerage firms have already submitted their reports for CNTA stocks, with Jefferies repeating the rating for CNTA by listing it as a “Buy.” The predicted price for CNTA in the upcoming period, according to Jefferies is $11 based on the research report published on November 15, 2023 of the previous year 2023.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CNTA reach a price target of $8, previously predicting the price at $4. The rating they have provided for CNTA stocks is “Equal-Weight” according to the report published on October 26th, 2023.
CNTA Trading at 14.12% from the 50-Day Moving Average
After a stumble in the market that brought CNTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.66% of loss for the given period.
Volatility was left at 7.38%, however, over the last 30 days, the volatility rate increased by 6.78%, as shares surge +9.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.53% upper at present.
During the last 5 trading sessions, CNTA rose by +14.46%, which changed the moving average for the period of 200-days by +72.03% in comparison to the 20-day moving average, which settled at $11.16. In addition, Centessa Pharmaceuticals plc ADR saw 49.12% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNTA starting from Anderson Karen M., who sale 51,160 shares at the price of $11.88 back on Mar 25 ’24. After this action, Anderson Karen M. now owns 71,525 shares of Centessa Pharmaceuticals plc ADR, valued at $607,960 using the latest closing price.
Rotman Harris, the SVP Regulatory Affairs of Centessa Pharmaceuticals plc ADR, sale 4,267 shares at $8.10 during a trade that took place back on Feb 01 ’24, which means that Rotman Harris is holding 62,625 shares at $34,574 based on the most recent closing price.
Stock Fundamentals for CNTA
Current profitability levels for the company are sitting at:
- -24.82 for the present operating margin
- 0.88 for the gross margin
The net margin for Centessa Pharmaceuticals plc ADR stands at -21.9. The total capital return value is set at -0.53. Equity return is now at value -53.01, with -37.59 for asset returns.
Based on Centessa Pharmaceuticals plc ADR (CNTA), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -2.12. The debt to equity ratio resting at 0.32. The interest coverage ratio of the stock is -17.32.
Currently, EBITDA for the company is -171.13 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 163.33. The receivables turnover for the company is 0.18for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.00.
Conclusion
In conclusion, Centessa Pharmaceuticals plc ADR (CNTA) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
